Fennec Pharmaceuticals (NASDAQ:FENC) Releases Earnings Results, Misses Expectations By $0.26 EPS

Fennec Pharmaceuticals (NASDAQ:FENC) posted its quarterly earnings results on Tuesday. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.26), Zacks reports. The business had revenue of $7.26 million during the quarter, compared to analysts’ expectations of $13.67 million. Fennec Pharmaceuticals had a negative return on equity of 39.41% and a net margin of 6.33%. During the same period in the prior year, the business posted ($0.21) earnings per share.

Fennec Pharmaceuticals Trading Up 3.2 %

NASDAQ FENC traded up $0.17 on Thursday, reaching $5.50. The stock had a trading volume of 52,236 shares, compared to its average volume of 122,636. The company has a quick ratio of 6.72, a current ratio of 6.93 and a debt-to-equity ratio of 9.86. The stock has a fifty day moving average price of $6.33 and a two-hundred day moving average price of $8.30. Fennec Pharmaceuticals has a 12-month low of $5.26 and a 12-month high of $11.92. The firm has a market capitalization of $150.30 million, a price-to-earnings ratio of 177.67 and a beta of 0.29.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on FENC. Wedbush restated an “outperform” rating and issued a $14.00 price target (down from $16.00) on shares of Fennec Pharmaceuticals in a research report on Tuesday. Craig Hallum dropped their price target on shares of Fennec Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, HC Wainwright reduced their price target on shares of Fennec Pharmaceuticals from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, May 15th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.